Neuware - Nanotechnology-Based Innovations in Chronic Obstructive Pulmonary Disease (COPD) Treatment and Management explores innovative drug delivery systems utilizing nanotechnology to revolutionize the treatment and management of COPD. By presenting the latest advancements in nanotechnologies-including polymeric nanoparticles, liposomes, and theranostic nanoparticles-this volume aims to enhance patient outcomes, alleviate symptoms, and improve lung function, thereby addressing the urgent need for more effective therapies. Structured to cater to a diverse audience, from beginners to advanced researchers, this comprehensive text begins with an overview of COPD, its epidemiology, and current limitations in treatment. The core chapters explore a wide range of nanotechnological applications for diagnosis and disease management, including cutting-edge topics such as nano-immunotherapy and green nanotechnology. Each chapter was developed by a multidisciplinary team of experts from academia and industry, ensuring a comprehensive approach that integrates insights from pharmaceutical sciences, respiratory health, and bioinformatics. Nanotechnology-based Innovations in Chronic Obstructive Pulmonary Disease (COPD) Treatment and Management not only fills a critical gap in COPD literature but also serves as an invaluable resource for researchers, clinicians, and students alike. It promises to be a definitive guide on how innovative drug delivery systems can transform COPD care, paving the way for future advancements in respiratory health management.

Seller Inventory # 9780443439469

Contact seller

Report this item

Bibliographic Details

Title: Nanotechnology-Based Innovations in Chronic Obstructive Pulmonary Disease (COPD) Treatment and Management
Publisher: Elsevier Science Publishing Co Inc Feb 2026
Publication Date: 2026
Language: English
ISBN 10: 044343946X
ISBN 13: 9780443439469
Binding: Taschenbuch
Condition: Neu
Dimensions: 236 millimeters width by 194 millimeters height by 28 millimeters depth
Weight: 1084 grams

About this title

Synopsis

Nanotechnology-Based Innovations in Chronic Obstructive Pulmonary Disease (COPD) Treatment and Management explores innovative drug delivery systems utilizing nanotechnology to revolutionize the treatment and management of COPD. By presenting the latest advancements in nanotechnologies―including polymeric nanoparticles, liposomes, and theranostic nanoparticles―this volume aims to enhance patient outcomes, alleviate symptoms, and improve lung function, thereby addressing the urgent need for more effective therapies. Structured to cater to a diverse audience, from beginners to advanced researchers, this comprehensive text begins with an overview of COPD, its epidemiology, and current limitations in treatment. The core chapters explore a wide range of nanotechnological applications for diagnosis and disease management, including cutting-edge topics such as nano-immunotherapy and green nanotechnology. Each chapter was developed by a multidisciplinary team of experts from academia and industry, ensuring a comprehensive approach that integrates insights from pharmaceutical sciences, respiratory health, and bioinformatics. Nanotechnology-based Innovations in Chronic Obstructive Pulmonary Disease (COPD) Treatment and Management not only fills a critical gap in COPD literature but also serves as an invaluable resource for researchers, clinicians, and students alike. It promises to be a definitive guide on how innovative drug delivery systems can transform COPD care, paving the way for future advancements in respiratory health management.

Highlights cutting-edge nanotechnologies transforming COPD treatment and management for improved patient outcomes
Discusses future directions and challenges in nanotechnology applications for COPD management
Serves as a valuable resource for researchers, clinicians, and students in respiratory health fields
Offers comprehensive coverage of innovative drug delivery systems for effective COPD diagnosis and therapy
Integrates multidisciplinary insights from experts in pharmaceutical sciences, respiratory health, and bioinformatics

About the Authors

Dr. Harish Dureja is Professor and Head, Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak. Dr. Dureja is also the Director, Centre for IPR Studies and Director, Professional Consultancy Cell. Dr. Dureja has more than 22 years of teaching experience. He also holds 18 years research experience in the field of nanoparticulate drug delivery, regulatory affairs and in silico ADME modeling. Dr. Dureja has been awarded with Gold-Medal for the best Ph.D. thesis and research projects worth 1.2 Crore from various funding agencies. He has filed an Indian patent and written a book and authored more than twenty five book chapters. He has published 265 publications in various international and national journals of repute. He worked as Chairman-Scientific Services Committee (LOC) during 69th IPC at Chitkara University, Raj-pura. He also worked as content writer for e-Pathashala program of Ministry of Human Resources Development for Post Graduate course of Pharmaceutical Sciences for the paper novel drug delivery system. He has delivered more than 180 invited Lectures in various conferences, seminars and symposiums and has guided 60 PG scholars and 10 students for doctoral work. He has been awarded the Gold-Medal for Best Ph.D. Thesis, Best Paper Award - Prof. M.L. Khorana Memorial Prize Award – 2005 and Dr. R.L. Nicore award - 2018. He has published six special issues as a Guest Editor for the Journals published by Bentham Science Publishers, and one issue published by Frontiers, Switzerland. He is currently also serving as President, Association of Pharmaceutical Teachers of India (APTI), Haryana State Branch.

Dr Ronan MacLoughlin, PhD MBS, is currently director of Research and Development, Science and Emerging Technologies in Aerogen limited and Irish medical device company specializing in respiratory drug delivery. He has more than 25 years of experience in the design and development of aerosol drug delivery systems and drug/device combination products. He currently has more than 120 articles, and multiple conference presentations and conference papers combined with several patents. He holds the position of adjunct associate professor in Trinity College Dublin’s (Ireland) Department of Pharmaceutics and Pharmaceutical Technology, honorary Senior Lecturer in the Royal College of Surgeons Ireland (RCSI), nonexecutive director on the board of several startup and scaling Med tech and pharmaceutical companies. Additionally, he is currently chair of the pediatric and cystic fibrosis working group within the International Society for aerosols in medicine. In 2024 he was honored with the Thomas T Mercer award, recognizing Dr MacLoughlin’s excellence in the areas of pharmaceutical aerosols and inhalable materials.development of drug delivery systems and drug device combinations, he has >220 collaborative publications,
as well as 12 granted patents.

His most recent focus has been on enabling several clinical programs making use of aerosolised prophylactics
and therapeutics for COVID-19, and his work on delivery of inhaled vaccines has resulted in the
world’s first approval for an orally inhaled vaccine for COVID-19 (Convidecia Air). His contribution to the
state of the art in fugitive medical and patient-derived aerosols was central to the evolution of several
critical care consensus statements around the safe use of aerosol therapy during the COVID-19 pandemic.

Dr. John I. Disouza is a Professor in Pharmaceutics, and Principal, at Tatyasaheb Kore College of Pharmacy, Warananagar, India. He has 20 years of teaching and research experience. Prof. Disouza has published more than 100 research papers, 3 books, and 8 book chapters. He is chief editor of the journal ‘Pharmacumconsequat’ and editor for Centum, and has also served as a guest editor for DDTR. Prof. Disouza is the chairperson of the IPA-Education division for Maharashtra state, a member of the Executive Board of the national IPA-Education division, and EC member of Controlled Release Society- Indian Chapter.

Muralikrishnan Dhanasekaran, is a Professor of Pharmacology and Toxicology at the Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University. He earned his Ph.D. in 1999 from the Jadavpur University, India, in neuropharmacology. From 1999-2001, he became a post-doctoral fellow at the University of Nebraska Medical Center, Omaha, Nebraska, and the Uni-versity of North Dakota School of Medicine and Health Sciences, Grand Forks, ND. He served as a re-search instructor of pharmacology at Texas A & M Health Sciences, Temple, TX. His major area of teaching and research is related to pathophysiology, pharmacology, and toxicology in dementia, movement disorders, addiction (substances of abuse-designer drugs, nicotine, alcohol), hyperglycemia, epilepsy, and aging. His research was funded by the Alzheimer’s Association and Pharmaceutical com-panies in the USA. He has over one hundred and thirteen peer-reviewed publications, fifty book chap-ters, and around four hundred abstracts in national and international meetings in the area of pharma-cology, toxicology, and natural bioactives. He has received several awards for teaching, service, and outreach. He has been an editor or on the editorial board for several books and journals including nat-ural products, pharmacology, toxicology, and neuropharmacology.

Kamal Dua is a Professor in the NICM Health Research Institute and the School of Science at Western Sydney University (WSU). Dr Dua has been recognised and named as one of Australia’s Top 250 researchers in 2026, 2025 and 2024 in Research Magazine by “The Australian� in the research discipline of Health and Medical sciences, and #1/research leader in the area of Pharmacology and Pharmacy (2026, 2025) and Toxicology (2024) respectively. With over 17 years of research experience, he has specialised in drug delivery targeting inflammatory diseases. Additionally, Dr Dua also leads drug delivery research at the Woolcock Institute of Medical Research. In this role, he focuses on advancing targets identified in research projects to develop innovative formulations, taking the first steps toward clinical translation. Dr Dua’s research encompasses two complementary areas: drug delivery and immunology. His work explores how these disciplines can mutually benefit, contributing to the goal of promoting longer and healthier lives for the community. His commitment to synergy is reflected in his extensive publication record in reputable journals. Dr Dua’s research interests are centered on harnessing the pharmaceutical potential of modulating critical regulators, such as interleukins and microRNAs. He also specialises in developing new and effective drug delivery formulations for managing inflammation in chronic airway diseases and cancer.

"About this title" may belong to another edition of this title.

Store Description

Das Unternehmen AHA-BUCH GmbH: Seit der Gr�ndung von AHA-BUCH im Juli 2005 ist unser Hauptziel, zufriedenen Kunden so schnell und so preisg�nstig wie m�glich ihren B�cherwunsch zu erf�llen. Unsere Firma besch�ftigt 16 Mitarbeiter, die nur ein Ziel kennen: den Kunden und seine W�nsche! Auf �ber 3700 m2 Fl�che haben wir �ber 100.000 B�cher, Modernes Antiquariat und Spiele auf Lager.

Visit Seller's Storefront

Seller's business information

AHA-BUCH GmbH
Garlebsen 48, Einbeck, 37574, Germany

Sale & Shipping Terms

Terms of Sale

General Terms and Conditions and Customer Information / Privacy Policy

I. General Terms and Conditions

� 1 Basic provisions

(1) The following terms and conditions apply to all contracts that you conclude with us as a provider (AHA-BUCH GmbH) via the Internet platforms AbeBooks and/or ZVAB. Unless otherwise agreed, the inclusion of any of your own terms and conditions used by you will be objected to

(2) A consumer within the meaning of the following regulations is any natural person who concludes...

More Information

Right of cancellation

**Right of withdrawal for consumers **

(A consumer is any natural person who concludes a legal transaction for purposes that can predominantly be attributed neither to their commercial nor their independent professional activity.)

Cancellation
Withdrawal
You have the right to revoke this contract within fourteen days without giving reasons.
The revocation period is fourteen days from the day,

on which you or a third party named by you, who is not the carrier, has taken possession of the goods, provided that you have ordered one or more goods within the framework of a uniform order and these are or will be delivered uniformly;
on which you or a third party named by you, who is not the carrier, has taken possession of the last goods, provided that you have ordered several goods within the framework of a single order and these are delivered separately;
on which you or a third party named by you, who is not the carrier, has taken possession of the last partial shipment or the last piece, provided that you have ordered goods that are delivered in several partial shipments or pieces;

In order to exercise your right of withdrawal, you must inform us (AHA-BUCH GmbH, Garlebsen 48, 37574 Einbeck, telephone number: 05563 9996039, fax number: 05563 9995974, e-mail address: service@aha-buch.de) of your decision to revoke this contract by means of a clear declaration (e.B. a letter sent by post, fax or e-mail). You can use the attached model withdrawal form, but this is not mandatory.

To comply with the revocation period, it is sufficient that you send the notification of the exercise of the right of revocation before the expiry of the revocation period.

Consequences of revocation

If you withdraw from this contract, we shall reimburse you all payments that we have received from you, including delivery costs (with the exception of the additional costs resulting from the fact that you have chosen a different type of delivery than the cheapest standard delivery offered by us), immediately and at the latest within fourteen days from the day on which we received the notification of your revocation of this contract.
For this repayment, we will use the same means of payment that you used for the original transaction, unless expressly agreed otherwise with you; in no case will you be charged any fees for this repayment.

We may withhold reimbursement until we have received the goods back or until you have provided proof that you have returned the goods, whichever is the earlier.

You must return or hand over the goods to us immediately and in any case at the latest within fourteen days from the day on which you inform us of the revocation of this contract. The deadline is met if you send the goods before the expiry of the period of fourteen days.

You bear the direct costs of returning the goods.

You only have to pay for any loss of value of the goods if this loss of value is due to handling of the goods that is not necessary to check the nature, characteristics and functioning of the goods.

Reasons for exclusion or extinction

The right of revocation does not apply to contracts

for the delivery of goods which are not prefabricated and for the manufacture of which an individual choice or determination by the consumer is decisive or which are clearly tailored to the personal needs of the consumer;
for the delivery of goods that can spoil quickly or whose expiry date would be exceeded quickly;
for the delivery of alcoholic beverages, the price of which was agreed at the time of conclusion of the contract, but which can be delivered at the earliest 30 days after conclusion of the contract and whose current value depends on fluctuations in the market over which the entrepreneur has no influence;
for the delivery of newspapers, magazines or magazines with the exception of subscription contracts.

The right of revocation expires prematurely in the case of contracts

for the delivery of sealed goods that are not suitable for return for reasons of health protection or hygiene, if their seal has been removed after delivery;
for the delivery of goods if they have been inseparably mixed with other goods after delivery due to their nature;
for the delivery of sound or video recordings or computer software in a sealed package, if the seal has been removed after delivery.

Sample withdrawal form

(If you want to cancel the contract, please fill out this form and send it back.)

To AHA-BUCH GmbH, Garlebsen 48, 37574 Einbeck, fax number: 05563 9995974, e-mail address: service@aha-buch.de :
I/we () hereby revoke the contract concluded by me/us () for the purchase of the following goods ()/
the provision of the following service ()
Ordered on ()/ received on ()
Name of the consumer(s)
Address of the consumer(s)
Signature of the consumer(s) (only in case of notification on paper)
Date

(*) Delete as appropriate.

Shipping Terms

We ship your order after we received them
for articles on hand latest 24 hours,
for articles with overnight supply latest 48 hours.
In case we need to order an article from our supplier our dispatch time depends on the reception date of the articles, but the articles will be shipped on the same day.

Our goal is to send the ordered articles in the fastest, but also most efficient and secure way to our customers.

Shipping rates from Germany to U.S.A.

Shipping rates from Germany to U.S.A.
Order quantity	30 to 40 business days	7 to 14 business days
First item	� 56.98	� 65.69

Delivery times are set by sellers and vary by carrier and location. Orders passing through Customs may face delays and buyers are responsible for any associated duties or fees. Sellers may contact you regarding additional charges to cover any increased costs to ship your items.

Detailed Seller Information